Fig. 8: PMD-026 ameliorates disease burden in PDX models of myeloid malignancies.

a Schematic of the PDX model setup and mutation burden of five patient samples utilized to establish PDX models. b Efficacy in the 201943 MF model. Plots show the percentage of hCD45 + cells in the PB and BM of transplanted mice treated with vehicle, 60 mg/kg ruxolitinib, 100 mg/kg PMD-026, or combination (n = 5 per group), spleen, liver weights of mice at endpoint normalized by mouse weight, and survival data. %hCD45 + in PB statistics comparing treatment group to control assessed by one-way ANOVA with Dunnett’s multiple comparisons; PMD-026 to combo by two-way Student’s t test. %hCD45 + in BM, and normalized spleen and liver weights statistics were assessed by one-way ANOVA with Dunnett’s multiple comparisons. Data are presented as mean values +/− SD. Kaplan-Meier survival analysis. Statistics were assessed by log-rank test between treatment groups as indicated. c Efficacy in the 290375 sAML model. Data are presented as mean values +/− SD. %hCD45 + in PB (n = 5 in vehicle; n = 6 in PMD-026) statistics assessed by two-way ANOVA. %hCD45 + in BM (n = 5 in vehicle; n = 6 in PMD-026) statistics assessed by two-tailed Student’s t test. d Efficacy in the 310914 sAML model. Data are presented as mean values +/− SD. %hCD45 + in PB (n = 5 per group) statistics assessed by two-way ANOVA. %hCD45 + in BM (n = 4 in vehicle; n = 5 in PMD-026) statistics assessed by two-tailed Student’s t test. e Efficacy in the 728508 sAML model. Data are presented as mean values +/− SD. %hCD45 + in PB (n = 5 per group) statistics assessed by two-way ANOVA. %hCD45 + in BM (n = 5 per group) statistics assessed by two-tailed Student’s t test. f Efficacy in the 676151 CMML model. Data are presented as mean values +/− SD. %hCD45 + in PB (n = 5 per group) statistics assessed by two-way ANOVA. %hCD45 + in BM assessed by two-tailed Student’s t test.